biological tumor markers

Summary

Summary: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.

Top Publications

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
  2. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
  3. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
  4. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
  5. ncbi American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
  6. ncbi Reporting recommendations for tumor marker prognostic studies (REMARK)
    Lisa M McShane
    Biometric Research Branch, National Cancer Institute, Executive Plaza North, 6130 Executive Blvd, Bethesda, MD 20892 7434, USA
    J Natl Cancer Inst 97:1180-4. 2005
  7. ncbi Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
  8. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
  9. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
  10. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998

Detail Information

Publications279 found, 100 shown here

  1. ncbi New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    P Therasse
    European Organization for Research and Treatment of Cancer, Brussels, Belgium
    J Natl Cancer Inst 92:205-16. 2000
    ..Methods of assessing tumor lesions are better codified, briefly within the guidelines and in more detail in Appendix I. All other aspects of response evaluation have been discussed, reviewed, and amended whenever appropriate...
  2. ncbi Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  3. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  4. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  5. ncbi American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
    Lyndsay Harris
    Yale Cancer Center, Yale University, New Haven, CT, USA
    J Clin Oncol 25:5287-312. 2007
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of breast cancer...
  6. ncbi Reporting recommendations for tumor marker prognostic studies (REMARK)
    Lisa M McShane
    Biometric Research Branch, National Cancer Institute, Executive Plaza North, 6130 Executive Blvd, Bethesda, MD 20892 7434, USA
    J Natl Cancer Inst 97:1180-4. 2005
    ....
  7. ncbi Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
    Soonmyung Paik
    Division of Pathology, Operations Center, and Biostatistical Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:3726-34. 2006
    ..The relationship between the RS and chemotherapy benefit is not known...
  8. ncbi Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
    D J Slamon
    Department of Medicine, U C L A School of Medicine 90024
    Science 244:707-12. 1989
    ..The data presented further support the concept that the HER-2/neu gene may be involved in the pathogenesis of some human cancers...
  9. ncbi Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma
    Torsten O Nielsen
    Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:5367-74. 2004
    ..Currently, there exist clinical assays that identify ER+/luminal and HER2-overexpressing tumors, and we sought to develop a clinical assay for breast basal-like tumors...
  10. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998
    ..In the future, these and other factors will be incorporated into a prognostic index that will better reflect the biologic diversity of breast cancer and that will more accurately predict clinical outcome...
  11. ncbi Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells
    Li Bing Song
    State Key Laboratory of Oncology in Southern China, Sun Yat sen University Cancer Center, Guangzhou, China
    Cancer Res 66:6225-32. 2006
    ....
  12. ncbi EGFR and cancer prognosis
    R I Nicholson
    Tenovus Cancer Research Centre, Welsh School of Pharmacy, Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff CF10 3XF, UK
    Eur J Cancer 37:S9-15. 2001
    ..Finally, it is important to stress that failure to detect a prognostic significance for EGFR in any one cancer type does not necessarily preclude patients from benefiting from anti-EGFR therapies...
  13. ncbi Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets
    Claus Lindbjerg Andersen
    Molecular Diagnostic Laboratory, Department of Clinical Biochemistry, Aarhus University Hospital, Skejby, DK 8200 Aarhus N, Denmark
    Cancer Res 64:5245-50. 2004
    ..The presented strategy can be applied to evaluate the suitability of any normalization gene candidate in any kind of experimental design and should allow more reliable normalization of RT-PCR data...
  14. ncbi X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization
    Robert L Camp
    Department of Pathology, Yale University, School of Medicine, New Haven, Connecticut 06520, USA
    Clin Cancer Res 10:7252-9. 2004
    ....
  15. doi Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    Rafael G Amado
    Amgen, Inc, One Amgen Center Dr, MS 38 2 B, Thousand Oaks, CA 91320 1799, USA
    J Clin Oncol 26:1626-34. 2008
    ..Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not been established in randomized trials...
  16. ncbi DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Ken A Olaussen
    Laboratory of Radiobiology and Oncology, Commissariat a l Energie Atomique, Fontenay aux Roses, University of Paris 11, Paris, France
    N Engl J Med 355:983-91. 2006
    ..Adjuvant cisplatin-based chemotherapy improves survival among patients with completely resected non-small-cell lung cancer, but there is no validated clinical or biologic predictor of the benefit of chemotherapy...
  17. ncbi The PIK3CA gene is mutated with high frequency in human breast cancers
    Kurtis E Bachman
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Department of Oncology, Baltimore, Maryland 21231, USA
    Cancer Biol Ther 3:772-5. 2004
    ..These results demonstrate that PIK3CA is the most mutated oncogene in breast cancer and support a role for PIK3CA in epithelial carcinogenesis...
  18. ncbi Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells
    Michael F Clarke
    Stanford University School of Medicine, Stanford, California, USA
    Cancer Res 66:9339-44. 2006
  19. ncbi Proliferation marker Ki-67 in early breast cancer
    Ander Urruticoechea
    Academic Department of Biochemistry, Royal Marsden Hospital, London SW3 6JJ, United Kingdom
    J Clin Oncol 23:7212-20. 2005
    ..However, its application as a pharmacodynamic intermediate marker of the effectiveness of medical therapy holds great promise for rapid evaluation of new drugs...
  20. pmc Network-based classification of breast cancer metastasis
    Han Yu Chuang
    Bioinformatics Program, University of California San Diego, La Jolla, CA 92093, USA
    Mol Syst Biol 3:140. 2007
    ..We find that the subnetwork markers are more reproducible than individual marker genes selected without network information, and that they achieve higher accuracy in the classification of metastatic versus non-metastatic tumors...
  21. ncbi ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer
    Gershon Y Locker
    American Society of Clinical Oncology Tumor Markers Expert Panel, Alexandria, VA 22314, USA
    J Clin Oncol 24:5313-27. 2006
    ..To update the recommendations for the use of tumor marker tests in the prevention, screening, treatment, and surveillance of gastrointestinal cancers...
  22. ncbi Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
    Bruce G Haffty
    Department of Radiation Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903 2681, USA
    J Clin Oncol 24:5652-7. 2006
    ..To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients...
  23. ncbi Gene expression profiling of primary cutaneous melanoma and clinical outcome
    Veronique Winnepenninckx
    Department of Pathology, Gustave Roussy Institute, 94805 Villejuif Cedex, France
    J Natl Cancer Inst 98:472-82. 2006
    ..To identify differentially expressed genes that may be involved in melanoma progression and prognosis, we investigated the relationship between gene expression profiles and clinical outcome in a cohort of patients with primary melanoma...
  24. ncbi Biomarkers in cancer staging, prognosis and treatment selection
    Joseph A Ludwig
    Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Cancer 5:845-56. 2005
    ..Understanding how and when biomarkers can be integrated into clinical care is crucial if we want to translate the promise into reality...
  25. pmc Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Breast Cancer Res 2:252-7. 2000
    ..Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours..
  26. ncbi Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer
    Zhen Zhang
    Department of Pathology, Biomarker Discovery Center, Johns Hopkins Medical Institutions, Baltimore, Maryland 21231, USA
    Cancer Res 64:5882-90. 2004
    ..These biomarkers demonstrated the potential to improve the detection of early stage ovarian cancer...
  27. ncbi Gene expression profiling of breast cell lines identifies potential new basal markers
    E Charafe-Jauffret
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Inserm Institut Paoli Calmettes, Marseille, France
    Oncogene 25:2273-84. 2006
    ....
  28. doi Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma
    Danit Lebanony
    Rosetta Genomics Ltd, 10 Plaut St, Rehovot 76706, Israel
    J Clin Oncol 27:2030-7. 2009
    ..In this study, we set out to identify specific microRNA biomarkers for the identification of squamous cell carcinoma, and to use such markers for the development of a standardized assay...
  29. pmc A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
    Richard G Moore
    Program in Women s Oncology, Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 112:40-6. 2009
    ..The objective of this trial was to validate a predictive model to assess the risk for EOC in women with a pelvic mass...
  30. ncbi Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer
    Yixin Wang
    Veridex, LLC, a Johnson and Johnson Company, 3210 Merryfield Row, San Diego, CA 92121, USA
    J Clin Oncol 22:1564-71. 2004
    ..In this study, we used DNA chip technology to systematically identify new prognostic markers for tumor relapse in Dukes' B patients...
  31. ncbi Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas
    Ronny Drapkin
    Department of Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Res 65:2162-9. 2005
    ..Its expression in cortical inclusion cysts suggests that formation of Mullerian epithelium is a prerequisite step in the development of some types of EOCs...
  32. ncbi Micro-RNA profiling in kidney and bladder cancers
    Fedra Gottardo
    Department of Urology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Urol Oncol 25:387-92. 2007
    ..To study the role of the micro-RNAs in human kidney and bladder cancer, we analyzed the expression profile of 245 micro-RNAs in kidney and bladder primary tumors...
  33. pmc Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future
    R D Riley
    Department of Epidemiology and Public Health, University of Leicester, Leicester, UK
    Br J Cancer 88:1191-8. 2003
    ..Such changes in practice would help important evidence-based reviews to be conducted in order to establish the most appropriate prognostic markers for clinical use, which should ultimately improve patient care...
  34. ncbi Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation
    William C S Cho
    Department of Clinical Oncology, Room 1305, 3 F, Block R, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong
    Eur J Cancer 45:2197-206. 2009
    ..The present study focuses on the microRNA (miRNA) expression profiles of this important subset of lung cancer...
  35. ncbi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  36. ncbi Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review
    M Berwick
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 92:874-97. 2000
    ..The evolving ability to study polymorphisms in DNA repair genes may contribute to new understandings about the mechanisms of DNA repair and the way in which DNA repair capacity affects the development of cancer...
  37. ncbi Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival
    J Rubin Grandis
    Department of Otolaryngology, University of Pittsburgh School of Medicine, and University of Pittsburgh Cancer Institute, PA, USA
    J Natl Cancer Inst 90:824-32. 1998
    ....
  38. ncbi The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  39. ncbi Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
    Nozomu Yanaihara
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Cell 9:189-98. 2006
    ..These results indicate that miRNA expression profiles are diagnostic and prognostic markers of lung cancer...
  40. ncbi Molecular identification of an IgE-dependent histamine-releasing factor
    S M MacDonald
    Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA
    Science 269:688-90. 1995
    ..Polyclonal antibodies recognized and removed the biological activity of recombinant and native HRF. HRF identifies a heterogeneity of IgE and is believed to play a prominent role in chronic allergic disease processes...
  41. ncbi Prognostic factors in non-small cell lung cancer: a decade of progress
    Michael D Brundage
    Department of Oncology, Radiation Oncology Research Unit, Queen s University, Kingston, ON, Canada
    Chest 122:1037-57. 2002
    ....
  42. ncbi Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  43. ncbi Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer
    D M Aebersold
    Department of Radiation Oncology, University of Bern, Switzerland
    Cancer Res 61:2911-6. 2001
    ....
  44. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
    ..We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases...
  45. doi Immunohistochemical characteristics of melanoma
    Steven J Ohsie
    Department of Pathology and Laboratory Medicine, Geffen UCLA School of Medicine, Los Angeles, CA 90095 1732, USA
    J Cutan Pathol 35:433-44. 2008
    ..Ki67 remains the most useful adjunct in distinguishing benign from malignant melanocytic tumors. None of the markers reviewed has been shown conclusively to have prognostic value for melanocytic neoplasms...
  46. ncbi Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer
    K S Goonetilleke
    Department of Surgery, Hepatobiliary Surgical Unit, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
    Eur J Surg Oncol 33:266-70. 2007
    ..This systematic review examines studies using biochemical markers for the diagnosis of pancreatic cancer in order to appraise their role in contemporary management algorithms...
  47. ncbi 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology
    R C Bast
    American Society of Clinical Oncology, Alexandria, VA 22314, USA
    J Clin Oncol 19:1865-78. 2001
    ..These guidelines are intended for use in the care of patients outside of clinical trials...
  48. pmc A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer
    Shuji Ogino
    Center for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 100:1734-8. 2008
    ..In conclusion, tumoral LINE-1 hypomethylation is independently associated with shorter survival among colon cancer patients...
  49. pmc Symbiotic bacteria direct expression of an intestinal bactericidal lectin
    Heather L Cash
    Center for Immunology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA
    Science 313:1126-30. 2006
    ..We propose that these proteins represent an evolutionarily primitive form of lectin-mediated innate immunity, and that they reveal intestinal strategies for maintaining symbiotic host-microbial relationships...
  50. doi Enabling personalized cancer medicine through analysis of gene-expression patterns
    Laura J Van't Veer
    Agendia BV, Louwesweg 6, 1066 EC Amsterdam, The Netherlands
    Nature 452:564-70. 2008
    ..In particular, tests that predict the clinical outcome for patients on the basis of the genes expressed by their tumours are likely to increasingly affect patient management, heralding a new era of personalized medicine...
  51. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
  52. ncbi Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    ..New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer...
  53. ncbi Molecular definition of breast tumor heterogeneity
    Michail Shipitsin
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Cancer Cell 11:259-73. 2007
    ..Our data suggest prognostic relevance of CD44+ cells and therapeutic targeting of distinct tumor cell populations...
  54. pmc Plk phosphorylation regulates the microtubule-stabilizing protein TCTP
    Frederic R Yarm
    Department of Molecular and Cellular Biology, Harvard University, Cambridge, Massachusetts 02138, USA
    Mol Cell Biol 22:6209-21. 2002
    ..These results suggest that phosphorylation decreases the microtubule-stabilizing activity of TCTP and promotes the increase in microtubule dynamics that occurs after metaphase...
  55. ncbi Breast cancer metastasis: markers and models
    Britta Weigelt
    Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nat Rev Cancer 5:591-602. 2005
    ..These data have important implications for prognosis prediction and our understanding of metastasis...
  56. ncbi Self-renewal and solid tumor stem cells
    Muhammad Al-Hajj
    University of Michigan Medical School, CCGC Room 4410, 1500 E Medical Center Drive, Ann Arbor 48109 0936, USA
    Oncogene 23:7274-82. 2004
    ..This suggests that agents that target the defective self-renewal pathways in cancer cells might lead to improved outcomes in the treatment of these diseases...
  57. ncbi The Ki-67 protein: from the known and the unknown
    T Scholzen
    Division of Molecular Immunology, Research Center Borstel, Germany
    J Cell Physiol 182:311-22. 2000
    ..There are indications, however, that Ki-67 protein expression is an absolute requirement for progression through the cell-division cycle...
  58. pmc An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer
    Andrew E Teschendorff
    Breast Cancer Functional Genomics Laboratory, Cancer Research UK Cambridge Research Institute and Department of Oncology, University of Cambridge, Robinson Way, Cambridge CB2 0RE, UK
    Genome Biol 8:R157. 2007
    ..Reliable identification of ER-negative tumors that have a good prognosis is not yet possible...
  59. pmc Early detection of ovarian cancer
    Donna Badgwell
    Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Dis Markers 23:397-410. 2007
    ..The development of technologies that measure multiple serum markers simultaneously, linked to the creation of statistical methods that enhance sensitivity without sacrificing specificity hold great promise...
  60. ncbi Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast
    L G Fulford
    The Breakthrough Breast Cancer Research Centre, London, UK
    Histopathology 49:22-34. 2006
    ..Currently, they are not identified in routine practice and no morphological guidelines exist to aid their identification. The aim of this study was to analyse the histological features of CK14+ IDC...
  61. ncbi Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules
    Giuseppe Costante
    Dipartimento di Medicina Sperimentale e Clinica, Università Magna Graecia, Italy
    J Clin Endocrinol Metab 92:450-5. 2007
    ..Routine serum calcitonin (CT) measurement in patients with thyroid nodules for diagnosis of medullary thyroid carcinoma (MTC) is controversial...
  62. doi Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Via Ripamoniti 435, Milan, Italy
    J Natl Cancer Inst 100:207-12. 2008
    ..Thus, Ki-67 labeling index was an independent prognostic factor but was not predictive of better response to adjuvant chemotherapy in these studies...
  63. pmc High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer
    Tibor A Rauch
    Divisions of Biology, Information Sciences, and Surgery, Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA
    Proc Natl Acad Sci U S A 105:252-7. 2008
    ..The results are consistent with a specific defect in methylation of repetitive DNA sequences in human cancer...
  64. pmc Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics
    Mollie H Wright
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, 9000 Rockville Pike, Bethesda, Maryland 20892, USA
    Breast Cancer Res 10:R10. 2008
    ..Whether cancer stem cells occur in BRCA1-associated breast cancer and contribute to therapeutic response is not known...
  65. ncbi Gene silencing in cancer in association with promoter hypermethylation
    James G Herman
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA
    N Engl J Med 349:2042-54. 2003
  66. ncbi Frequent EpCam protein expression in human carcinomas
    Philip Th Went
    Institute for Pathology, University of Basel, Basel, Switzerland
    Hum Pathol 35:122-8. 2004
    ..Most soft-tissue tumors and all lymphomas were EpCam negative. It is concluded that anti-EpCam therapies, if proven to be successful, will have broad applications in a wide variety of carcinomas...
  67. pmc Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics
    Bryan T Hennessy
    Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 69:4116-24. 2009
    ..PIK3CA mutations, EMT, and stem cell-like characteristics likely contribute to the poor outcomes of MBC and suggest novel therapeutic targets...
  68. ncbi The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation
    Tiffany M Phillips
    Department of Radiation Oncology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1714, USA
    J Natl Cancer Inst 98:1777-85. 2006
    ..Cancer-initiating cells can now be prospectively isolated from breast cancer cell lines and tumor samples and propagated as mammospheres in vitro under serum-free conditions...
  69. ncbi Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer
    J S Nielsen
    University of Southern Denmark, Odense, Denmark
    Int J Gynecol Cancer 14:1086-96. 2004
    ..In the borderline group Her-2 and EGFR over-expression in combination, adjusted for age and p53, significantly improved the prognosis...
  70. ncbi Relevance of breast cancer cell lines as models for breast tumours: an update
    Marc Lacroix
    Laboratoire Jean Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Universite Libre de Bruxelles, Bruxelles, Belgium
    Breast Cancer Res Treat 83:249-89. 2004
    ..Investigations on additional specific lines are expected to improve our knowledge of BCC and of the dialogue that these maintain with their surrounding normal cells in vivo...
  71. ncbi Hypermethylation of CpG islands in primary and metastatic human prostate cancer
    Srinivasan Yegnasubramanian
    Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Cancer Res 64:1975-86. 2004
    ..Furthermore, CpG island hypermethylation patterns in prostate cancer metastases were very similar to the primary prostate cancers and tended to show greater differences between cases than between anatomical sites of metastasis...
  72. ncbi Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis
    Karen H Lu
    Ovarian Cancer Research Laboratory, Department of Experimental Therapeutics, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:3291-300. 2004
    ..Consequently, use of multiple markers in combination might detect a larger fraction of early-stage ovarian cancers...
  73. doi Assessment of a HER2 scoring system for gastric cancer: results from a validation study
    M Hofmann
    Institute of Pathology, Klinikum Kassel, Kassel, Germany
    Histopathology 52:797-805. 2008
    ..The aim was to establish a HER2 scoring system for gastric cancer to identify suitable patients for enrollment in a trial of trastuzumab (Herceptin) in advanced metastatic gastric cancer...
  74. pmc MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma
    Aaron J Schetter
    Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    JAMA 299:425-36. 2008
    ..MicroRNAs have potential as diagnostic biomarkers and therapeutic targets in cancer. No study has evaluated the association between microRNA expression patterns and colon cancer prognosis or therapeutic outcome...
  75. ncbi Cell surface tumor endothelial markers are conserved in mice and humans
    E B Carson-Walter
    The Howard Hughes Medical Institute, Baltimore, Maryland 21231, USA
    Cancer Res 61:6649-55. 2001
    ..The coordinate expression of TEM1, TEM5, and TEM8 on tumor endothelium in humans and mice makes these genes attractive targets for the development of antiangiogenic therapies...
  76. pmc Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer
    Ying Xie
    Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA
    Lung Cancer 67:170-6. 2010
    ..The aim of this study was to determine whether aberrant miRNA expression can be used as a marker in sputum specimen for the diagnosis of non-small cell lung cancer (NSCLC)...
  77. ncbi HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
    C Gravalos
    Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain
    Ann Oncol 19:1523-9. 2008
    ..This review summarizes the rationale, preclinical evidence, retrospective clinical analyses, and the interim clinical data pertaining HER2 therapies in gastric cancer...
  78. pmc Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer
    Gennadi V Glinsky
    Sidney Kimmel Cancer Center, San Diego, California 92121, USA
    J Clin Invest 115:1503-21. 2005
    ....
  79. pmc Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53
    S W Beenken
    Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Ann Surg 233:630-8. 2001
    ..To assess the prognostic significance of molecular biomarkers, particularly c-erbB-2 and p53, through study of prospective clinical data and archival breast cancer tissues for women accrued to the Alabama Breast Cancer Project...
  80. pmc High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer
    Johan Staaf
    Department of Oncology, Clinical Sciences, Lund University, Barngatan 2B, Lund, Sweden
    Breast Cancer Res 12:R25. 2010
    ....
  81. ncbi CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity
    Shengyong Yin
    Department of General Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, People s Republic of China
    Int J Cancer 120:1444-50. 2007
    ..The implication that CD133 might be one of the markers for HCC cancer stem-like cells needed further investigation...
  82. pmc Development of personalized tumor biomarkers using massively parallel sequencing
    Rebecca J Leary
    Ludwig Center for Cancer Genetics and Therapeutics and Howard Hughes Medical Institute, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA
    Sci Transl Med 2:20ra14. 2010
    ..This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients...
  83. pmc Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design
    Margaret S Pepe
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    J Natl Cancer Inst 100:1432-8. 2008
    ..Common biases that pervade the biomarker research literature would be eliminated if these rigorous standards were followed...
  84. ncbi Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus
    Francine Walker
    Department of Pathology, Institut de la Santé et de la Recherche Médicale Unité773, Hopital Bichat Claude Bernard, 75018 Paris, France
    Hum Pathol 40:1517-27. 2009
    ..The finding that EGFR, c-Met, and VEGFR1 involved in carcinogenesis are well-represented and coexpressed in anal cancers, especially in HIV-positive population, suggests possible novel targeted treatments for anal diseases...
  85. ncbi A novel five-antibody immunohistochemical test for subclassification of lung carcinoma
    Brian Z Ring
    Department of Research and Development, Applied Genomics Inc, Burlingame, CA 94010, USA
    Mod Pathol 22:1032-43. 2009
    ..The results also suggest that if validated in prospectively defined clinical trials this classifier might identify candidates for targeted therapy that are overlooked with current diagnostic approaches...
  86. pmc Periostin is frequently overexpressed and enhances invasion and angiogenesis in oral cancer
    B S M S Siriwardena
    Department of Oral Maxillofacial Pathobiology, Division of Frontier Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1 2 3 Kasumi, Hiroshima, Japan
    Br J Cancer 95:1396-403. 2006
    ..In summary, these findings suggest that Periostin may promote invasion and angiogenesis in OSCC, and that Periostin can be a strong marker for prediction of metastasis in oral cancer patients...
  87. ncbi Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues
    Junming Guo
    Ningbo University School of Medicine, Ningbo 315211, Zhejiang Province, China
    J Gastroenterol Hepatol 24:652-7. 2009
    ..MicroRNAs (miRNAs) play important roles in carcinogenesis. The global miRNA expression profile of gastric cancer has not been reported. The purpose of the present study was to determine the miRNA expression profile of gastric cancer...
  88. ncbi FOXA1 expression in breast cancer--correlation with luminal subtype A and survival
    Sunil Badve
    Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
    Clin Cancer Res 13:4415-21. 2007
    ..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
  89. doi Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck
    Pernille Lassen
    Department of Experimental Clinical Oncology, Aarhus University Hospital, Noerrebrogade 44, DK 8000 Aarhus C, Denmark
    J Clin Oncol 27:1992-8. 2009
    ....
  90. pmc Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis
    A Takeno
    Department of Surgery, Graduate School of Medicine, Osaka University, 2 2 Yamadaoka Suita, Osaka 565 0871, Japan
    Br J Cancer 99:1307-15. 2008
    ..This integrated approach could help to identify candidate players in gastric carcinogenesis and progression. These genes are potential markers of gastric cancer regardless of stage...
  91. ncbi Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Clin Cancer Res 14:2593-600. 2008
    ..To investigate the prognostic value of the molecular detection of circulating tumor cells (CTCs) using three markers [cytokeratin 19 (CK19), mammaglobin A (MGB1), and HER2] in early breast cancer...
  92. ncbi Basal carcinoma of the breast revisited: an old entity with new interpretations
    E Korsching
    Institute of Pathology, University of Muenster, Germany
    J Clin Pathol 61:553-60. 2008
    ..Clinical consequences and potential future research directions driven by the definition of basal breast cancers will also be discussed...
  93. doi Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer
    Alex Soltermann
    Institute for Surgical Pathology, Department of Pathology, University Hospital Zurich, Zurich, Switzerland
    Clin Cancer Res 14:7430-7. 2008
    ....
  94. ncbi The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
    Richard G Moore
    Women and Infants Hospital, Brown University, Providence, RI 02925, USA
    Gynecol Oncol 108:402-8. 2008
    ..Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125...
  95. ncbi Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer
    Peng Lee
    Department of Pathology, New York University Medical Center, New York, NY 10003, USA
    Gynecol Oncol 96:671-7. 2005
    ..We therefore examined the pattern of expression of ERs, PRs, and ARs in a large number of samples of primary ovarian carcinoma by using a tissue microarray technique...
  96. ncbi Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas
    Keith Hoek
    Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, 15 York Street, New Haven, CT 06520 8059, USA
    Cancer Res 64:5270-82. 2004
    ..These results provide a comprehensive view of changes in advanced melanoma relative to normal melanocytes and reveal new targets that can be used in assessing prognosis, staging, and therapy of melanoma patients...
  97. ncbi Application of mesothelin immunostaining in tumor diagnosis
    Nelson G Ordonez
    University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Surg Pathol 27:1418-28. 2003
    ..Finally, the strong mesothelin reactivity seen in the adenomatoid tumors (3 of 3) provides further support for a mesothelial derivation for this lesion...
  98. ncbi Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery
    Julio E Celis
    Danish Centre for Translational Breast Cancer Research, and Department of Proteomics in Cancer, Institute of Cancer Biology, The Danish Cancer Society, DK 2100 Copenhagen, Denmark
    Mol Cell Proteomics 3:327-44. 2004
    ....
  99. ncbi A review and update on cholangiocarcinoma
    Matthew J Olnes
    Department of Internal Medicine, Johns Hopkins Bayview Medical Center and Johns Hopkins School of Medicine, Baltimore, MD, USA
    Oncology 66:167-79. 2004
    ..Particular focus is on recent studies into the cellular and molecular pathogenesis of the disease, recent chemotherapy trials, and newer methods of staging and screening for this devastating malignancy...
  100. doi Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays
    Anders Carlsson
    Department of Immunotechnology, Lund University, BMC D13, SE 221 84 Lund, Sweden
    Eur J Cancer 44:472-80. 2008
    ..In a longer perspective, antibody microarray analysis could provide a tool for the development of improved diagnostics and intensified biomarker discovery for breast cancer patients...
  101. pmc Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection
    Shawn A Ritchie
    Phenomenome Discoveries Inc, Saskatoon, SK, Canada
    BMC Med 8:13. 2010
    ..Using tandem-mass spectrometry (MS/MS) high throughput MS technology we evaluated the utility of selected markers and this technology for discriminating between CRC and healthy subjects...

Research Grants175 found, 100 shown here

  1. Early Biomarkers of Lung cancer by Gene Array Analysis
    Susan Boggs; Fiscal Year: 2003
    ..Expression profiling is expected to provide a new approach for comparisons between normal and cancerous cells, as well as to suggest potential targets for intervention. ..
  2. Protein Biomarkers of Cancer Risk in Older Persons
    Christopher Li; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  3. DETERMINATION OF A NEW GROWTH FACTOR IN BREAST MILK
    DAVID TAPPER; Fiscal Year: 1990
    ..a critical role in modulating both normal and abnormal cellular proliferation and may have potential as biological tumor markers. During our prior granting period, we identified specific growth factor activities in milk of substrains ..
  4. Early Biomarkers of Lung cancer by Gene Array Analysis
    Susan Boggs; Fiscal Year: 2002
    ..Expression profiling is expected to provide a new approach for comparisons between normal and cancerous cells, as well as to suggest potential targets for intervention. ..
  5. NEW IMMUNOLOGIC APPROACHES TO LYMPHOID NEOPLASMS
    Eugene Frenkel; Fiscal Year: 1980
    ....
  6. Phase II Study of 44Gy from 131I-81C6 for CNS Tumors
    David Reardon; Fiscal Year: 2004
    ..To further define the toxicity of this approach and Specific Aim 3.To determine the impact of this therapy on quality of life. ..
  7. P21 INDUCTION BY BRCA2
    Fergus Couch; Fiscal Year: 2002
    ....
  8. A genome-wide association study for breast cancer in BRCA1 mutation carriers
    Fergus Couch; Fiscal Year: 2008
    ..The modifiers may also lead to development of improved risk assessment models that better discriminate between high and lower risk BRCA1 mutation carriers. ..
  9. Genetic epidemiology of cell division regulation in breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  10. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2002
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  11. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2009
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..
  12. Clinically-Integrated Randomized Trial of Radical Prostatectomy
    Andrew Vickers; Fiscal Year: 2008
    ..We intend to pilot this methodology in a trial comparing modifications to radical prostatectomy. ..
  13. Genetic epidemiology of cell division regulation in breast cancer
    Fergus Couch; Fiscal Year: 2008
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  14. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2003
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  15. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2007
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..
  16. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2008
    ..relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  17. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2004
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  18. Molecular signatures of HNSCC in response to targeted therapies
    Christine Chung; Fiscal Year: 2008
    ..Ultimately, we expect that the findings from this study will be translated into improved patient selection and optimized treatment benefits from EGFR inhibitors in HNSCC patients. ..
  19. Methodology of Phase I and II trials of anticancer CAM
    Andrew Vickers; Fiscal Year: 2004
    ....
  20. CLINICAL RESEARCH CURRICULUM
    David Ransohoff; Fiscal Year: 2004
    ..abstract_text> ..
  21. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  22. A genome-wide association study for breast cancer in BRCA1 mutation carriers
    Fergus Couch; Fiscal Year: 2009
    ..The modifiers may also lead to development of improved risk assessment models that better discriminate between high and lower risk BRCA1 mutation carriers. ..
  23. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2005
    ..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..
  24. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2004
    ..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..
  25. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2007
    ..relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  26. BRCA2 missense mutations and breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  27. Genetic epidemiology of cell division regulation in breast cancer
    FERGUS JOSEPH COUCH; Fiscal Year: 2010
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  28. Genetic epidemiology of cell division regulation in breast cancer
    Fergus Couch; Fiscal Year: 2009
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  29. BRCA2 missense mutations and breast cancer
    FERGUS JOSEPH COUCH; Fiscal Year: 2010
    ..study the cancer relevance of many missense mutations will have been determined and provided to the carriers who will then be able to benefit from improved cancer risk assessment, cancer prevention and perhaps even therapeutic strategies ..
  30. Genetic epidemiology of cell division regulation in breast cancer
    Fergus Couch; Fiscal Year: 2007
    ..The results will provide information for improved risk assessment and could provide targets for breast cancer prevention and therapeutic agents. ..
  31. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2005
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  32. Colonoscopy Utilization in North Carolina
    David Ransohoff; Fiscal Year: 2006
    ..It may provide the basis to develop interventions to optimize the allocation of colonoscopy effort in programs of CRC screening and surveillance. ..
  33. Novel Methods for Integrative Analysis of Cancer Genomic Data
    Shuangge Ma; Fiscal Year: 2010
    ..Applications of the proposed methods will lead to identification of clinically useful cancer markers. ..
  34. Characterization of the Chromosome 17q23 Amplicon
    Fergus Couch; Fiscal Year: 2006
    ..Thus, the project may involve a complete transition from benchtop to bedside. Finally, the amplified and overexpressed genes may prove useful as important targets of gene, pharmacological, and immunological therapy in the future. ..
  35. A genome-wide association study for breast cancer in BRCA1 mutation carriers
    FERGUS JOSEPH COUCH; Fiscal Year: 2010
    ..The modifiers may also lead to development of improved risk assessment models that better discriminate between high and lower risk BRCA1 mutation carriers. ..
  36. Role of CCN6 (WISP3) in the progression and metastasis of breast cancer
    Celina Kleer; Fiscal Year: 2008
    ..These studies may form the basis of intervention and therapy in breast cancer, potentially preventing premalignant lesions from becoming malignant and metastasizing. ..
  37. CORI: Consortium Expansion and Database Enhancement
    David Lieberman; Fiscal Year: 2004
    ....
  38. Bloodborne tissue factor-bearing microparticles in Trousseau's syndrome
    Jeffrey Zwicker; Fiscal Year: 2008
    ....
  39. Novel Targets of Indoles in Prostate Cancer
    Fazlul Sarkar; Fiscal Year: 2005
    ..abstract_text> ..
  40. Breast and Bone Density: Impact of Colonic Environment
    Johanna Lampe; Fiscal Year: 2005
    ..If equol-producer phenotype can predict differences in cumulative estrogen exposure / metabolism, it may serve as an early marker of breast cancer risk. ..
  41. Interaction of PTEN and CDKN1B in Pca susceptibility
    Jianfeng Xu; Fiscal Year: 2007
    ..The results from this study are likely to significant advance our knowledge of prostate cancer risk and begin to explore the underlying biological mechanisms for any observed differences. ..
  42. Novel Targets of Indoles in Prostate Cancer
    Fazlul Sarkar; Fiscal Year: 2004
    ..abstract_text> ..
  43. Clinical Outcomes Research: An Endoscopic Data Base
    David Lieberman; Fiscal Year: 2007
    ..We have demonstrated successful collaboration with a wide range of clinical investigators to develop projects that are uniquely suited to a large community-based practice network. [unreadable] [unreadable]..
  44. Assessing Treatment-Related Harms in Prostate Cancer
    H Welch; Fiscal Year: 2005
    ..The entire process will be repeated on a cohort of men who receive a transurethral resection of the prostate. ..
  45. DNA Adducts of the Carcinogen Acetaldehyde
    Stephen Hecht; Fiscal Year: 2007
    ..These studies will provide critical data on the occurrence and biological significance of acetaldehyde DNA adducts and their possible role in human cancer. ..
  46. Telomere dysfunction, oxidative damage and breast cancer risk
    Jing Shen; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  47. MOLECULAR REGULATION OF C-JUN BY IONIZING RADIATION
    Donald Kufe; Fiscal Year: 1992
    ....
  48. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2009
    ..abstract_text> ..
  49. COLLABORATIVE STUDY OF OVARIAN CANCER IN TWO RISK GROUPS
    MARC GOODMAN; Fiscal Year: 2002
    ..Dr. Anna Wu, the P.I. on the Los Angeles sub-contract during the first cycle of this grant, will assist with statistical analysis and the interpretation of results. ..
  50. Molecular physiology of mammalian INSP3 receptor
    J Kevin Foskett; Fiscal Year: 2009
    ..The results of these studies should provide new insights into the molecular physiology of this ubiquitous family of Ca2+ release channels. ..
  51. Cytosolic O-Glycosylation and Insulin Signaling
    Gerald Warren Hart; Fiscal Year: 2010
    ..Data from these experiments will reveal totally new avenues for developing treatments for diabetes. ..
  52. CATIONIC LIPID/P53 GENE THERAPY IN LUNG CANCER PATIENTS
    Roman Perez Soler; Fiscal Year: 2001
    ..The results of this study will provide initial but very valuable information on the potential use of this new strategy in the treatment of bronchial premalignancy, carcinoma in situ, and endobronchial lung tumors. ..
  53. Genetic profiling in PCPT: prostate cancer risk, PSA levels, and chemoprevention
    Jianfeng Xu; Fiscal Year: 2009
    ..Prostate cancer risk associated variants could also be used in combination with PSA and other existing clinical variables to considerably improve their predictive accuracy for positive prostate biopsy. 1 ..
  54. Phase III Trial of Exercise Training in Postsurgical Lung Cancer
    Lee Jones; Fiscal Year: 2009
    ..Despite its importance, effective interventions to improve exercise capacity among lung cancer patients are not available. ..
  55. Genetic Determinants of Lung Cancer Survival
    Ping Yang; Fiscal Year: 2010
    ..Our ultimate goal is to build comprehensive and clinically useful models in designing patient-specific treatment plans and in predicting patients'treatment response and survival. ..
  56. THERAPEUTIC MODULATION OF ANGIOGENESIS IN HUMAN GLIOMAS
    Erwin Van Meir; Fiscal Year: 2002
    ..Improving the treatment of malignant gliomas, an incurable disease, is an important human health goal. ..
  57. Screening for colortectal cancer in an Asian Community Center
    David Lieberman; Fiscal Year: 2008
    ..This is a new paradigm for screening, which takes advantage of the trust and cultural awareness that exists at the community center and does not rely on the primary care provider. [unreadable] [unreadable] [unreadable] [unreadable]..
  58. EASTERN COOPERATIVE ONCOLOGY GROUP
    Joseph Sparano; Fiscal Year: 2008
    ....
  59. Function of Sialomucin Complex/Muc4 in Mammary Tumors
    KERMIT CARRAWAY; Fiscal Year: 2003
    ..These studies are directed toward providing the evidence for SMC/MUC4 contributions to tumor progression as a prelude to developing methods for therapeutic targeting of this component. ..
  60. A Serum Marker for Aggressive Prostate Cancer
    Donna M Peehl; Fiscal Year: 2010
    ....
  61. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2006
    ..This molecular analysis may also greatly improve diagnostic prediction compared to the cellular pattern recognition currently used by pathologists. [unreadable] [unreadable]..
  62. A Serum Marker for Aggressive Prostate Cancer
    Donna Peehl; Fiscal Year: 2006
    ....
  63. Tamoxifen & Second Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2007
    ..which women have increased or decreased risks of developing CBC if they use tamoxifen? (4) Among the CBC cases, how does tamoxifen alter the expression of these tumor markers in first compared to contralateral cancers? ..
  64. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2007
    ..This molecular analysis may also greatly improve diagnostic prediction compared to the cellular pattern recognition currently used by pathologists. [unreadable] [unreadable]..
  65. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2006
    ..abstract_text> ..
  66. Advancing Child Health through Cellular and Molecular Biology
    Valerie Castle; Fiscal Year: 2007
    ....
  67. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2009
    ..such as parity and body mass index, modify this association?;and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  68. Risk Factors for Second Primary Breast Cancer Among DCIS Survivors
    Christopher I Li; Fiscal Year: 2010
    ....
  69. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2006
    ..such as parity and body mass index, modify this association?; and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  70. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  71. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  72. c-erbB-2 and Risk of Contralateral Breast Cancer
    Christopher Li; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  73. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2008
    ..such as parity and body mass index, modify this association?; and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  74. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2008
    ..abstract_text> ..
  75. Molecular Profiling of Premalignant Oral Lesions
    Mark Lingen; Fiscal Year: 2008
    ..This molecular analysis may also greatly improve diagnostic prediction compared to the cellular pattern recognition currently used by pathologists. [unreadable] [unreadable]..
  76. A Serum Marker for Aggressive Prostate Cancer
    Donna Peehl; Fiscal Year: 2008
    ....
  77. Proteomics Biomarkers Development Laboratory
    Samir Hanash; Fiscal Year: 2008
    ..abstract_text> ..
  78. Advancing Child Health through Cellular and Molecular Biology
    Valerie Castle; Fiscal Year: 2008
    ....
  79. ER Reporter Genes To Predict Response To Endocrine Therapy
    WILLIAM SYMMANS; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  80. A Serum Marker for Aggressive Prostate Cancer
    Donna Peehl; Fiscal Year: 2007
    ....
  81. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2009
    ..such as parity and body mass index, modify this association?;and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  82. A Serum Marker for Aggressive Prostate Cancer
    Donna Peehl; Fiscal Year: 2009
    ....
  83. KALLIKREINS AS DIAGNOSTIC MARKERS OF OVARIAN CARCINOMA
    Eleftherios Diamandis; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  84. Molecular Mechanisms in the Treatment of Neuroblastoma
    Valerie Castle; Fiscal Year: 2005
    ..abstract_text> ..
  85. Oral Cancer, Chemoprevention, and Anti-Angiogenesis
    Mark Lingen; Fiscal Year: 2005
    ..abstract_text> ..
  86. ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS
    Mark Lingen; Fiscal Year: 2000
    ....
  87. REGULATION OF APOPTOSIS IN NEUROBLASTOMA
    Valerie Castle; Fiscal Year: 2000
    ..The investigator feels these experiments will address the molecular link between the benign lesions and malignant neuroblastoma. ..
  88. Tamoxifen & Second Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2005
    ..which women have increased or decreased risks of developing CBC if they use tamoxifen? (4) Among the CBC cases, how does tamoxifen alter the expression of these tumor markers in first compared to contralateral cancers? ..
  89. Depo-Provera and Breast Cancer: Epidemiology/Pathology
    Christopher Li; Fiscal Year: 2005
    ..such as parity and body mass index, modify this association?; and (3) Does the association between DMPA and breast cancer risk vary by histologic type or by the expression of steroid receptors including ERq, ERft, and PR? ..
  90. Analysis to enhance sensitivity for membrane proteins
    Samir Hanash; Fiscal Year: 2002
    ....
  91. REGULATION OF APOPTOSIS IN NEUROBLASTOMA
    Valerie Castle; Fiscal Year: 1999
    ..The investigator feels these experiments will address the molecular link between the benign lesions and malignant neuroblastoma. ..
  92. Protein Biomarkers of Cancer Risk in Older Persons
    Christopher Li; Fiscal Year: 2005
    ....
  93. Molecular Mechanisms in the Treatment of Neuroblastoma
    Valerie Castle; Fiscal Year: 2003
    ..abstract_text> ..
  94. ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS
    Mark Lingen; Fiscal Year: 2002
    ....
  95. ORAL CANCER, RETINOIDS, AND ANTIANGIOGENESIS
    Mark Lingen; Fiscal Year: 2001
    ....